CLEVELAND – SPR Therapeutics, a provider of neurostimulation technology for pain, has received clearance from the U.S. Food and Drug Administration for its SPRINTendura(single lead) and extensa(dual lead) Peripheral Nerve Stimulation systems. “Our SPRINT PNS platform is designed to deliver the least invasive and most user-friendly PNS therapy experience for physicians and their patients,” said Maria Bennett, founder, president and CEO of SPR Therapeutics, in a statement. The SPRINT PNS platform features: a dual-lead capability that allows physicians to implant two leads connected to a single wearable pulse generator; rechargeable batteries that allow continuous stimulation delivery; and a Bluetooth enabled controller that fosters patient-specific customization and ease of use. Bennett said that preliminary results from a federally funded multicenter study of SPRINT for the treatment of chronic post-amputation pain demonstrate that significant reductions in pain or pain interference were reported among two-thirds of subjects following an eight-week treatment period. Enduring and significant pain relief was reported by 80% of patients who completed the entire 12-month study.
You are here: / / FDA clears PNS systems for chronic pain